ArticleInternational ophthalmology2026
Evaluation of serum myelin basic protein in POAG patients at a tertiary institution in Lagos, Nigeria.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlaucoma, a neurodegenerative disorder, causes retinal ganglion cell damage and loss of neurons in the visual system up to the visual cortex. The loss of myelin sheath leads to the release of myelin sheath components, including the myelin basic protein (MBP), into the bloodstream. While MBP has shown promise as a biomarker for glaucoma in some Asian populations, data among individuals of African descent remain limited. This study evaluated the serum levels of MBP in primary open-angle glaucoma (POAG) patients compared to non-glaucoma controls, with the aim of reporting its usefulness as a biomarker for glaucoma detection in an African population.
methodsThis cross-sectional study compared serum MBP levels in treatment-naive primary open-angle glaucoma (POAG) patients and non-glaucoma controls. Blood samples were collected from 83 treatment-naive POAG participants and 83 age and sex matched non-glaucoma participants and analyzed using enzyme-linked immunosorbent assay (ELISA).
resultsThe mean age of POAG participants was 50.78 ± 17.3 years, with a male predilection. The mean intraocular pressure (IOP) was significantly higher in POAG patients (18.22 ± 6.8 mmHg) than in controls (13.89 ± 2.5 mmHg). Serum MBP levels were significantly elevated in POAG patients (1128.75 ng/L) compared to controls (963.75 ng/L; p < 0.001). There was no significant correlation between MBP levels and disease severity. MBP levels were higher in high-tension glaucoma and females; however, the difference was not statistically significant.
conclusionFindings supported the neurodegenerative state of POAG and the use of serum MBP levels as a potential biomarker for early POAG detection.
Indexed as
Identifiers
42799797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.